The U.S. Food and Drug Administration recently approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) for ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, ...

A year ago, Pfizer tied a subcutaneous injection of the highest dose of the anti-GDF-15 antibody ponsegromab once every four ...

Halozyme Therapeutics has been busy. While fighting a patent dispute with Merck & Co. | Halozyme scoured very broadly for ...

Hamlin was given the treatment as part of a clinical trial after receiving a diagnosis of melanoma last year. She recently ...

Earlier this month, BioArctic AB announced that Leqembi Iqlik, the subcutaneous autoinjector formulation of lecanemab, became available in the U.S. as a maintenance dosing option for early Alzheimer's ...

GSK’s ViiV Healthcare and its bimonthly pre-exposure prophylaxis (PrEP) medicine Apretude had to make room for another ...

A new study offers hope for brain cancer patients facing memory loss from radiotherapy. By blocking a single immune receptor, ...

While anyone can contract mpox, according to the Centers for Disease Control and Prevention (CDC), those at higher risk ...

Alphamab Oncology (Stock Code: 9966.HK) announced that the first interim analysis results of a phase III clinical trial of anbenitamab injection (KN026), independently developed by the Company and ...

Chances are, you may know a family living with food allergies. Food allergies are more prevalent than many realize, ...

Tucatinib enhances progression-free survival (PFS) in HER2+ metastatic breast cancer, showcasing promising results in a ...